These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 31910099)
1. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products. Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099 [TBL] [Abstract][Full Text] [Related]
2. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080 [TBL] [Abstract][Full Text] [Related]
3. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211 [TBL] [Abstract][Full Text] [Related]
4. Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study. Cai Y; Sui L; Wang J; Qian W; Peng Y; Gong L; Wu W; Gao Y BMC Med; 2024 Sep; 22(1):421. PubMed ID: 39334246 [TBL] [Abstract][Full Text] [Related]
5. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
6. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. López-Beas J; Guadix JA; Clares B; Soriano-Ruiz JL; Zugaza JL; Gálvez-Martín P Med Res Rev; 2020 Jul; 40(4):1315-1334. PubMed ID: 32017179 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union. Jokura Y; Yano K; Yamato M J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195 [TBL] [Abstract][Full Text] [Related]
8. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]. Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546 [TBL] [Abstract][Full Text] [Related]
9. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe. Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839 [TBL] [Abstract][Full Text] [Related]
10. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea. Choi M; Han E; Lee S; Kim T; Shin W Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218 [TBL] [Abstract][Full Text] [Related]
12. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. Chisholm J; Ruff C; Viswanathan S Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821 [TBL] [Abstract][Full Text] [Related]
13. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan. Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339 [TBL] [Abstract][Full Text] [Related]
14. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. Nagai S; Ozawa K Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858 [TBL] [Abstract][Full Text] [Related]
15. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA. Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594 [TBL] [Abstract][Full Text] [Related]
16. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany. Renner M; Anliker B; Sanzenbacher R; Schuele S Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214 [TBL] [Abstract][Full Text] [Related]
18. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products. Lucas-Samuel S; Ferry N; Trouvin JH Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213 [TBL] [Abstract][Full Text] [Related]
19. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851 [TBL] [Abstract][Full Text] [Related]
20. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]